NASDAQ:RARE Ultragenyx Pharmaceutical Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $62.65 +2.99 (+5.01%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$58.65▼$63.2850-Day Range$45.80▼$75.6652-Week Range$45.20▼$104.38Volume451,391 shsAverage Volume491,992 shsMarket Capitalization$4.38 billionP/E RatioN/ADividend YieldN/APrice Target$111.29 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ultragenyx Pharmaceutical Stock Forecast (MarketRank)Analyst RatingModerate Buy2.58 Rating ScoreUpside/Downside75.2% Upside$109.75 Price TargetShort InterestBearish4.18% of Float Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment0.00Based on 5 Articles This WeekInsider TradingSelling Shares$27.32 K Sold Last QuarterProj. Earnings GrowthGrowingFrom ($7.15) to ($5.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.99 out of 5 starsMedical Sector311th out of 1,429 stocksPharmaceutical Preparations Industry126th out of 682 stocks 3.3 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $109.75, Ultragenyx Pharmaceutical has a forecasted upside of 75.2% from its current price of $62.65.Amount of Analyst CoverageUltragenyx Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.18% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 0.37%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 1.7 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ultragenyx Pharmaceutical this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,321.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.49% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($7.15) to ($5.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -9.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -9.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address About Ultragenyx Pharmaceutical (NASDAQ:RARE)Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.Read More RARE Stock News HeadlinesJuly 1, 2022 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Ultragenyx PharmaceuticalJune 27, 2022 | americanbankingnews.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $111.29June 24, 2022 | seekingalpha.comEMA panel recommends extending indication for low blood phosphate treatment CrysvitaJune 23, 2022 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Erik Harris Sells 295 Shares of StockJune 23, 2022 | americanbankingnews.comStockNews.com Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to SellJune 16, 2022 | americanbankingnews.comComparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Ovid Therapeutics (NASDAQ:OVID)June 14, 2022 | nasdaq.comIonis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan TagJune 14, 2022 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Upgraded by StockNews.com to "Hold"June 13, 2022 | finance.yahoo.comUltragenyx Pharmaceutical (NASDAQ:RARE) shareholders have endured a 51% loss from investing in the stock a year agoJune 1, 2022 | finance.yahoo.comUltragenyx to Present at Jefferies Global Healthcare ConferenceMay 24, 2022 | markets.businessinsider.comExpert Ratings for Ultragenyx PharmaceuticalMay 19, 2022 | finance.yahoo.comUltragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual MeetingMay 17, 2022 | seekingalpha.comUltragenyx to buy global rights to Abeona's gene therapy ABO-102 for fatal brain condition in kidsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,119Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/01/2022Next Earnings (Estimated)8/01/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$109.75 High Stock Price Forecast$142.00 Low Stock Price Forecast$73.00 Forecasted Upside/Downside+77.6%Consensus RatingModerate Buy Rating Score (0-4)2.58333333333333 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($6.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-454.02 million Net Margins-141.65% Pretax Margin-141.28% Return on Equity-49.18% Return on Assets-30.20% Debt Debt-to-Equity RatioN/A Current Ratio4.23 Quick Ratio4.12 Sales & Book Value Annual Sales$351.41 million Price / Sales12.47 Cash FlowN/A Price / Cash FlowN/A Book Value$13.53 per share Price / Book4.63Miscellaneous Outstanding Shares69,930,000Free Float65,245,000Market Cap$4.38 billion OptionableOptionable Beta1.61 Ultragenyx Pharmaceutical Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Ultragenyx Pharmaceutical stock. View analyst ratings for Ultragenyx Pharmaceutical or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price forecast for 2022? 12 Wall Street research analysts have issued 12-month price objectives for Ultragenyx Pharmaceutical's stock. Their RARE stock forecasts range from $73.00 to $142.00. On average, they predict Ultragenyx Pharmaceutical's share price to reach $109.75 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price. View analysts' price targets for Ultragenyx Pharmaceutical or view top-rated stocks among Wall Street analysts. How has Ultragenyx Pharmaceutical's stock price performed in 2022? Ultragenyx Pharmaceutical's stock was trading at $84.09 at the start of the year. Since then, RARE shares have decreased by 25.5% and is now trading at $62.65. View the best growth stocks for 2022 here. When is Ultragenyx Pharmaceutical's next earnings date? Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022. View our earnings forecast for Ultragenyx Pharmaceutical. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($2.19) EPS for the quarter, missing analysts' consensus estimates of ($1.76) by $0.43. The biopharmaceutical company had revenue of $79.94 million for the quarter, compared to analysts' expectations of $84.25 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 49.18% and a negative net margin of 141.65%. Ultragenyx Pharmaceutical's revenue was down 19.6% compared to the same quarter last year. During the same period last year, the company posted ($2.03) EPS. View Ultragenyx Pharmaceutical's earnings history. Who are Ultragenyx Pharmaceutical's key executives? Ultragenyx Pharmaceutical's management team includes the following people: Dr. Emil D. Kakkis M.D., Ph.D., Pres, CEO & Director (Age 62, Pay $1.28M)Ms. Mardi C. Dier, Exec. VP & CFO (Age 58, Pay $812.24k) (LinkedIn Profile)Mr. John Richard Pinion II, Chief Quality Operations Officer & Exec. VP of Translational Sciences (Age 56, Pay $743.58k) (LinkedIn Profile)Dr. Camille L. Bedrosian M.D., Chief Medical Officer & Exec. VP (Age 69, Pay $825.08k) (LinkedIn Profile)Mr. Erik Harris, Exec. VP & Chief Commercial Officer (Age 51, Pay $797.57k) (LinkedIn Profile)Mr. Theodore A. Huizenga, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 51) (LinkedIn Profile)Mr. Dennis Karl Huang, Chief Technical Operations Officer & Exec. VP (Age 57) (LinkedIn Profile)Ms. Danielle Keatley, Sr. Director of Investor Relations & Corp. CommunicationsMs. Karah Herdman Parschauer J.D., Gen. Counsel & Exec. VP (Age 44) (LinkedIn Profile)Mr. Ernie W. Meyer, Chief HR Officer & Exec. VP (Age 58) What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees. Who are some of Ultragenyx Pharmaceutical's key competitors? Some companies that are related to Ultragenyx Pharmaceutical include BeiGene (BGNE), Shiseido (SSDOY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Ono Pharmaceutical (OPHLF), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Organon & Co. (OGN), Legend Biotech (LEGN) and Grifols (GRFS). View all of RARE's competitors. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $62.65. How much money does Ultragenyx Pharmaceutical make? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $4.38 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454.02 million in net income (profit) each year or ($6.87) on an earnings per share basis. How many employees does Ultragenyx Pharmaceutical have? Ultragenyx Pharmaceutical employs 1,119 workers across the globe. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at [email protected], or via fax at 415-483-8810. This page (NASDAQ:RARE) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
